



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>4</sup> :</b> <b>A61K 31/57, 7/06</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 85/ 05272</b> <b>(43) International Publication Date:</b> 5 December 1985 (05.12.85)
<b>(21) International Application Number:</b> PCT/GB85/00218 <b>(22) International Filing Date:</b> 22 May 1985 (22.05.85) <b>(31) Priority Application Number:</b> 8413069 <b>(32) Priority Date:</b> 22 May 1984 (22.05.84) <b>(33) Priority Country:</b> GB <b>(71)(72) Applicant and Inventor:</b> MORTIMER, Christopher, Harry [GB/GB]; 8 Park Square West, Regents Park, London NW1 4LJ (GB). <b>(74) Agent:</b> BOULT, WADE & TENNANT; 27 Furnival Street, London EC4A 1PQ (GB). <b>(81) Designated States:</b> AU, DK, JP, NO, US.		<b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TREATMENT OF FEMALE HAIR LOSS  <b>(57) Abstract</b>  A pharmaceutical formulation for use in treating female scalp hair loss or in hormonal replacement therapy which comprises medroxyprogesterone acetate or its pharmacologically-active equivalent and at least one oestrogen, wherein when prepared in unit dosage from the formulation is adapted to administer at least 1 mg and not more than 500 mg of medroxyprogesterone acetate or its pharmacologically-active equivalent per month, with the proviso that the said equivalent is not cyproterone acetate.		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

- 1 -

TREATMENT OF FEMALE HAIR LOSS

The present invention relates to the treatment of scalp hair loss and balding in women. This is a distressing condition which can affect women at the pre-, peri- post-menopause who have not previously experienced significant hair loss. Because thinning hair is not a socially acceptable condition in women, as it may be in men after a certain age, the condition can cause not merely distress but severe psychological symptoms in women involving feelings of loss of femininity and self confidence, depression and inability to concentrate of anything except the prospect of impending baldness with mounting embarrassment.

Associated with the menopause, a number of so-called "menopausal symptoms" may be experienced by a patient. It has been found that the present treatment, designed for arresting hair loss, also alleviates these menopausal symptoms, and hence is also suitable for use in long-term hormonal replacement therapy.

The present invention provides a pharmaceutical formulation for use in treating female scalp hair loss or in hormonal replacement therapy which comprises medroxyprogesterone acetate or its pharmacologically-active equivalent and at least one oestrogen, wherein when prepared in unit dosage form the formulation is adapted to administer at least 1mg and not more than 500mg of medroxyprogesterone acetate or its pharmacologically-active equivalent per month, with the proviso that the said equivalent is not cyproterone acetate.

Medroxyprogesterone acetate is a synthetic progesterone-like preparation (17 alpha hydroxy - 6

- 2 -

alpha - methyl - delta 4 - pregnen-3, 20 dione - 17  
alpha acetate) conveniently referred to as MPA. It  
has been used previously (as Provera) for the  
management of functional uterine bleeding, certain  
5 hormone dependent neoplasms (malignant diseases) such  
as endometrial carcinoma, hypernephroma, cancer of  
prostate.

It has now been found unexpectedly that scalp  
hair loss proceeding to baldness in women at the  
10 pre-, peri-, post-menopause can be arrested with the  
growth of new hair using a combination of at least  
one oestrogen with medroxyprogesterone acetate  
wherein, when prepared in unit dosage form, the  
formulation is adapted to administer at least 1mg and  
15 not more than 500mg of MPA per month. The invention  
further provides, in combination, a pharmaceutical  
formulation of the invention, a container therefor,  
and instructions for the use of the pharmaceutical  
formulation in the treatment of female scalp hair  
20 loss or in hormonal replacement therapy.

The formulations of the present invention may be  
designed for oral or parenteral administration.  
Although the formulations could be for administration  
by injection, they will most conveniently be for oral  
25 administration e.g. as tablets, capsules or solutions  
or suspensions.

They may however be formulated as creams or  
lotions for topical administration or as injectable  
solutions or suspensions for subcutaneous injection  
30 e.g. in the scalp or for other forms of injection.  
They may generally be formulated for any of the known  
routes of pharmaceutical administration.

Preferably, a formulation for oral administration  
will contain from 1 to 50mg, preferably 5 to 10mg, of  
35 MPA per unit dosage form e.g. per tablet.

- 3 -

The identity of the oestrogen used is not critical. Ethinyloestradiol is preferred. The oestrogen is present to provide a contraceptive effect, and in addition to provide the beneficial effect of raising plasma sex hormone binding globulin (SHBG) levels thereby diminishing free (biologically-active) testosterone and other androgen levels. A suitable dose rate for ethinyloestradiol would be 10-60µg per day orally, preferably about 40µg.

5 The treatment of female scalp hair loss will preferably involve the administration of medroxyprogesterone acetate and the oestrogen in a cyclic manner. In the first part of the cycle, preferably the oestrogen alone will be administered, 10 while in the second part of the cycle both oestrogen and MPA will be administered. This is followed 15 preferably by no treatment to allow for withdrawal bleeding.

Preferably, the cycle length is 28 days in accordance with normal contraceptive practice.

A possible oral dosage regimen would therefore be: Ethinyloestradiol 10-6µg daily for 28 days of each cycle;

Medroxyprogesterone acetate 1-50mg daily for up to 27 days of the cycle; 25 or more preferably;

Ethinyloestradiol at 30-40µg daily for the first 21 days of each cycle and;

MPA at 5-10mg daily from days 16 to 21 of the 30 cycle.

The dosage for oestrogens other than ethinyloestradiol will be well known to practitioners.

Whilst the dosages of oestrogen and MPA for administration on the same day may conveniently be 35 formulated together as a formulation according to the

- 4 -

invention, they can equally well be taken separately.

In either case it will be advantageous if the two different types of daily dose, namely oestrogen plus MPA or oestrogen alone are put up in a calendar pack as is the normal practice with contraceptive tablets.

Optionally, tablets containing neither active ingredients (dummy tablets) can be provided for the days when neither ingredient is to be taken.

Accordingly the present invention provides a calendar pack containing pharmaceutical formulation doses for use in treating female scalp hair loss or in hormonal replacement therapy, comprising spaced locations corresponding to days of a menstrual cycle, dosage forms in a first series of said locations providing at each location of the series a daily dose of an oestrogen in pharmaceutically-administrable form without medroxyprogesterone acetate or its pharmacologically-active equivalent, and dosage forms at a second series of locations following the first series providing a daily dose of the oestrogen and a daily dose of medroxyprogesterone acetate or its pharmacologically-active equivalent in pharmaceutically-administrable form, wherein the total dosage of medroxyprogesterone acetate or its equivalent in the pack is at least 1mg and not more than 500mg per cycle, with the proviso that the said equivalent is not cyproterone acetate.

An example of such pack would be a bubble pack of the conventional kind having a tablet or other dosage form contained in a bubble at each of a series of space locations, normally positioned in a closed loop running round the edge of the pack.

The locations may be numbered, normally 1 to 28.

The first series of bubbles may contain only one tablet or other dosage form per location containing

- 5 -

oestrogen but not MPA. The first series of bubbles containing oestrogen only will preferably correspond to up to the first 21 days, e.g. the first 16 days of a 28 day cycle.

5       The second series of locations may then contain either one tablet or other dosage form containing both active ingredients or a pair of tablets or other dosage forms per location, one containing oestrogen and the other MPA. Where two dosage forms are  
10       provided they may of course be put in separate bubbles at the same day's location. The second series may comprise enough locations to correspond to up to the first 27 days of a cycle, preferably from the 16th to the 21st day.

15       If further locations are provided, they may be empty so that they can simply be burst in turn to mark the day's passing or may contain a dosage form containing neither active ingredient.

      An example of a tablet formulation according to  
20       the present invention would, for instance, be:  
40ug ethinyloestradiol                   70.0mg lactose  
10mg medroxyprogesterone acetate       94.0mg corn starch  
10mg talcum                               3.2mg gelatin  
  2.8mg magnesium  
25   stearate

      It has been found that treatment described as above results in decreased hair fall, decrease in the greasiness of the hair, increased hair density  
30       together with the alleviation of the menopausal symptoms experienced by many women e.g. hot flushes, vaginal dryness, mild acne and greasy skin, depression, loss of confidence, decreased mental alertness and a general feeling of being unwell.

35

      It has been found that patients treated with Medroxyprogesterone Acetate or its pharmacologically

- 6 -

active equivalent, derivative or analogue and at least one oestrogen administered systemically as described in the Invention may unexpectedly benefit further from the addition of topical preparations applied directly to the scalp.

Therefore, it is proposed that the addition of topical preparations may enhance the effects of systemic preparations leading to the possible reduction in the dose of either the topical or systemic preparations to produce a synergistic therapeutic effect. For this reason it may be possible for the lower limits of the doses described previously to be reduced while maintaining the effectiveness of the preparations (systemic and topical) in the arrest and reversal of the common baldness process. Such a combination of therapy would be of considerable practical clinical value in allowing the minimum effective dose of treatment to be used.

#### CLINICAL EXAMPLES

Four patients aged 42-50 years had experienced hair loss beginning at the ages of 36-43 years for the first time. All patients had a regular menstrual cycle apart from one patient aged 45 years whose menopause had begun at the age of 37 years. Previous treatments, including iron tablets, yeast, various vitamins and standard hormone preparations (described below), had failed to arrest the hair fall which was progressive, although other menopausal symptoms had improved. The patients had received combinations of the following:

Premarin (Ayerst): containing conjugated



- 7. -

oestrogens (equine) 0.625mg or 1.25mg taken for 21 days starting on the 5th day of menstruation and then 7 tablet-free days.

- 5        Prempak (Ayerst): containing conjugated oestrogens (equine) 0.625mg or 1.25mg with norgestrel 0.5mg 7 tablets starting on the 5th day of menstruation and then 7 tablet-free days.

- 10       Premarin (Ayerst): containing conjugated oestrogens (equine) 0.625mg plus Duphaston (Duphar) dydrogesterone 10mg daily for 7 days from day 14.

Ovranette (Wyeth) containing ethinyloestradiol 30µg daily for 21 days combined with levonorgestrel 150µg daily for 21 days.

- 15       Brevinor (Syntex) containing ethinyloestradiol 35µg daily for 21 days combined with norethisterone 0.5mg daily for 21 days.

Ovysmen (Ortho-Cilag) containing ethinyloestradiol 35µg daily for 21 days with norethisterone 0.5mg for 21 days.

- 20       Norgeston (Schering) containing levonorgestrel 30µg continuously.

Following endocrine and trichological assessment, the patients were treated with:

- 25       Ethinyl-oestradiol: 30µg - 40µg daily for 21 days of each cycle. MPA: 5mg or 10mg daily from days 16 to 21 of the menstrual cycle.

Following the withdrawal bleed after 5-7 days, treatment was restarted.

- 30       Within 3 months each patient reported an improvement in hair condition, reduced greasiness and reduction in hair fall and an improvement in general wellbeing. Each patient also reported subsequently increased new hair growth and in particular the full growth previously of fine short hairs at the frontal margin.
- 35

- 8 -

The hair line had stopped receding and had moved forward with the growth of new hair. Treatment continued over 2-4 years with regular withdrawal bleeds, no pregnancies and with the retention of the hair growth achieved.

In the patients treated there were no unwanted side effects with normal haematology, liver function tests, renal function tests, general biochemistry and cervical smears repeated each 1-2 years remaining normal.

As will be appreciated, MPA can be replaced in the formulations of the present invention by any pharmacologically-active thereof at a corresponding dosage level. By this is meant any anti-androgen which has a progesterone-like action similar to MPA locally on scalp hair follicles, whilst at the same time does not significantly reduce SHBG levels. Suitable equivalents are allyloestrenol and gestronol. Hydroxprogesterone and dydrogesterone may be effective in some patients, but the latter only if the local dosage is high enough and certainly higher than 10 x 7 i.e. 70mg per month described above which was administered systemically.

Cyproterone acetate (CPA) is an equivalent of MPA, but since formulations similar to those of the present invention are described and claimed separately in my co-pending application No. (Agents' Ref: ) CPA formulations are specifically excluded from the scope of this application.

Additional information regarding an unexpected beneficial effect upon systemically administered Medroxyprogesterone Acetate or its pharmacologically active equivalent and at least one oestrogen by the

application of topical preparations.

The following topical preparations may be used in women in combination with the Invention as previously described in a volume of 1-10ml in divided doses to the affected sites on the scalp:

1) Preparation 1:

One or more of:

Oestradiol benzoate 0.2% (range 0.001-5%)

Medroxyprogesterone Acetate 0.2% (range 0.001-5%)

3,3-5 Triiodo-L-Thyronine Free Acid 20ug/3ml of solution up to 1%.

Or, metabolites or derivatives or analogues thereof.

2) Preparation 1 plus vasodilator:

One or more of:

Oestradiol Benzoate 0.1% (range 0.001-5%)

Medroxyprogesterone Acetate 0.1% (range 0.001-5%)

3,3-5 Triiodo-L-Thyronine Free Acid 20ug/ml of solution up to 1%.

Plus a vasodilator e.g.

a) Phentolomine Mesylate (as Rogitine, CIBA) 0.1% (range 0.001-10%)

b) Isoprenaline Hydrochloride 0.04% (range 0.001-10%)

c) Minoxidil 0.1%-4% (range 0.001-10%)

Or metabolites or derivatives or analogues thereof.

The addition of one or more vasodilators applied topically or given systemically could be included in the Invention. The nature of the vasodilators is not critical.

3) Preparation 2 plus "2nd Messenger"

One or more of:

Oestradiol Benzoate 0.2% (range 0.001-5%)

Medroxyprogesterone Acetate 0.2% (range 0.001-5%)

- 10 -

3,5 Triiodo-L-Thyronine Free Acid 20ug/3ml of  
solution up to 1% Vasodilator as described in 2,  
a,b and/or c above

- 5 "2nd Messenger" as:  
One or more of:  
Cyclic AMP Free Acid 0.1% (range 0.0000000001-20%)  
Cyclic AMP Sodium 0.05% (range 0.0000000001-20%)  
N6, 2-O-Dibutyryl Adenosine 3,5,Cyclic  
10 Monophosphate (a long acting synthetic form of  
Cyclic AMP) 0.01% (range 0.0000000001-20%)  
ATP Magnesium 0.1% (range 0.0000000001-20%)  
Choline Theophyllinate (phosphodiesterase  
inhibitor) 0.2% (range 0.001-20%)  
15 Caffeine (phosphodiesterase inhibitor) 0.2%  
(range 0.001-20%)  
Other "2nd Messengers" may be included according  
to the Invention e.g.  
One or more of:  
20 Cyclic GMP Free Acid 0.01%  
(range 0.0000000001-20%)  
Cyclic GMP Sodium 0.1% (range 0.0000000001-20%)  
N2,2-O-Dibutyryl Guanosine 3,5, Cyclic  
Monophosphate (a long acting synthetic form of  
25 Cyclic GMP) 0.01% (range 0.0000000001-20%)  
5, GDP  
5, GTP  
5,G Tetra P  
5, Guanylyl Imidodiphosphate (a long acting form  
30 of GTP)  
Inosine 3,5, Cyclic Monophosphate, Diphosphate,  
Triphosphate  
Thymidine 3,5, Cyclic Monophosphate, Diphosphate,  
Triphosphate

35

- 11 -

Uridine 3,5, Monophosphate, Diphosphate,  
Triphosphate

Or other "2nd Messenger" systems, derivatives or  
analogues thereof at a dose range of

5 0.000000000.1-20% or phosphodiesterase inhibitors.

4) Preparation 1,2, or 3 plus enzymes of the Embden  
Meyerhoff Parnass Pathway, the Pentose Phosphate  
Shunt or the Tricarboxylic Acid cycle to include:

10 One or more of:

Phosphorylase 625 IU/L (range 1-100,000)

Hexokinase 1,000 IU/L (range 1-100,000)

Glucose-6-Phosphate

Dehydrogenase 1,00 IU/L (range 1-100,000)

15 Phosphofructokinase

1,000 IU/L (range 1-100,000)

Or other enzyme systems at a dose range of

1-100,000 IU/L.

20 5) Preparations 1,2,3 or 4 plus:

Para Amino Benzoic Acid or salts or derivatives  
thereof 0.1% to 0.3% (range 0.0001-20%)

6) Preparations 1,2,3,4 or 5 plus:

25 One or more other anti-androgens e.g.

Spironolactone 0.1-3% (range 0.001-20%)

Deoxycorticosterone 0.2% (range 0.001-20%)

Climetidine 0.1% (range 0.001-20%)

Desogestrel 0.1% (range 0.001-20%)

30 Megestrol Acetate 0.1% (range 0.001-20%)

Ethinodiol Diacetate 0.1% (range 0.001-20%)

Cyproterone Acetate 0.1% (range 0.001-20%)

Lynoestrenol 0.1% (range 0.001-20%)

Norethisterone 0.1% (range 0.001-20%)

35 Levonorgestrel 0.1% (range 0.001-20%)

- 12 -

Flutamide 0.1% (range 0.001-20%)  
Progesterone 0.1% (range 0.001-20%)  
Azelaic Acid 0.1% (range 0.001-20%)  
Testolactone 0.1% (range 0.001-20%)  
5 Danazol 0.1% (range 0.001-20%)  
Or other anti-androgens or metabolites or  
derivatives or analogues thereof.

7) Preparations 1,2,3,4,5, or 6 plus:

10 One or more of:  
Immunosuppressives  
Amino Acids such as those normally found in the hair  
Glucose or other energy source.

15 When the topical preparations as set out above (some  
components of which may be given systemically e.g.  
Triiodothyronine as the sodium salt given orally in the  
range of 1ug-300ug daily, more preferable 20ug three  
times daily) are administered in addition to the  
20 systemic cyclical anti-androgen therapy as described  
in the Invention there has resulted a clear increase  
in the rate of growth of scalp hair. Typically  
patients have reported that prior to the addition of  
the topical preparations they would normally cut their  
25 hair each 2-3 months to maintain the same style.  
However, the addition of the above preparations has  
resulted in hair being required to be cut each 4-6  
weeks to maintain the same hair style. The rate of  
growth is increased particularly in the temporal and  
30 occipital areas with an increase in rate of growth in  
these areas being noted before that in the frontal and  
vertex regions. Typically the rate of hair growth has  
increased by approximately 25-200% during the first  
3-6 months of treatment.

35

## CLAIMS:

1. A pharmaceutical formulation for use in treating female scalp hair loss or in hormonal replacement therapy which comprises medroxyprogesterone acetate or its pharmacologically-active equivalent and at least one oestrogen, wherein when prepared in unit dosage form the formulation is adapted to administer at least 1mg and not more than 500mg of medroxyprogesterone acetate or its pharmacologically-active equivalent per month, with the proviso that the said equivalent is not cyproterone acetate.
2. A formulation as claimed in claim 1 further comprising a pharmaceutically-acceptable carrier, diluent or excipient.
3. A formulation as claimed in claim 1 or 2 in the form of a unit dosage form for oral administration
4. A formulation as claimed in claim 3 which provides from 1 to 50mg of medroxyprogesterone acetate per unit dosage form.
5. A formulation as claimed in claim 4 which provides 5 to 10mg of medroxyprogesterone acetate per unit dosage form.
6. A formulation as claimed in any preceding claim wherein the or each oestrogen present is ethinyloestradiol or its pharmacologically-active equivalent.
7. A formulation as claimed in claim 6 when

appendant to any one of claims 3 to 5 wherein the formulation provides from 10 to 60µg per unit dosage form of ethinyloestradiol.

5           8. A formulation as claimed in claim 7 wherein the formulation provides about 40µg per unit dosage form of ethinyloestradiol.

9. A formulation as claimed in any one of claims  
10       3 to 5, claim 7 or claim 8 in the form of a tablet, capsule, solution or suspension.

10. A formulation as claimed in claim 1, claim 2  
15       or claim 6 in the form of an ointment, cream or lotion, or an injectable solution or suspension.

11. A formulation as claimed in claim 1 and substantially as hereinbefore described.

20           12. A calendar pack containing pharmaceutical formulation doses for use in treating female scalp hair loss or in hormonal replacement therapy, comprising spaced locations corresponding to days of a menstrual cycle, dosage forms in a first series of  
25       said locations providing at each location of the series a daily dose of an oestrogen in pharmaceutically-administrable form without medroxyprogesterone acetate or its pharmacologically-active equivalent, and dosage forms at a second  
30       series of locations following the first series providing a daily dose of the oestrogen and a daily dose of medroxyprogesterone acetate or its pharmacologically-active equivalent in pharmaceutically-administrable form, wherein the  
35       total dosage of medroxyprogesterone acetate or its



equivalent in the pack is at least 1mg and not more than 500mg per cycle, with the proviso that the said equivalent is not cyproterone acetate.

5        13. A pack as claimed in claim 12 wherein the oestrogen in ethinyloestradiol or its pharmacologically-active equivalent.

10       14. A pack as claimed in claim 13 wherein the daily dose of oestrogen provided is 10 to 60mg of ethinyloestradiol.

15       15. A pack as claimed in claim 14 wherein the daily dosage of oestrogen provided is about 40mg of ethinyloestradiol.

20       16. A pack as claimed in any one of claims 12 to 15 wherein the locations of the second series each contain separate dosage forms providing medroxyprogesterone acetate or its equivalent and oestrogen respectively.

25       17. A pack as claimed in any one of claims 12 to 15 wherein the locations of the second series each contain a dosage form providing a mixture of medroxyprogesterone acetate or its equivalent and oestrogen.

30       18. A pack as claimed in any one of the claims 12 to 17 wherein the locations in the first series correspond to up to the first 21 days of a menstrual cycle.

35       19. A pack as claimed in claim 18 wherein the locations in the first series correspond to about the

first 16 days of a menstrual cycle.

20. A pack as claimed in any one of claims 12 to 19 wherein the locations in the second series  
5 correspond to the 16th to the 21st day of a menstrual cycle.

21. A pack as claimed in any one of claims 12 to 20 wherein each location in the second series  
10 contains a dose of from 1 to 50mg of medroxyprogesterone acetate.

22. A pack as claimed in claim 21 wherein each location in the second series contains a dose of from  
15 5 to 10mg of medroxyprogesterone acetate.

23. A pack as claimed in any one of claims 12 to 22 wherein each dosage form is a tablet or capsule.

20 24. A pack as claimed in any one of claims 12 to 23 wherein dosage forms containing neither oestrogen nor medroxyprogesterone acetate or its pharmacologically-active equivalent are provided at a third series of locations following the second series.  
25

25. A pack as claimed in claim 12 and substantially as hereinbefore described.

26. A pack as claimed in any one of claims 12 to 25 including instructions for the use of the  
30 pharmaceutical formulation in the treatment of female scalp hair loss or in hormonal replacement therapy.

27. In combination, a pharmaceutical formulation  
35 as claimed in any one of claims 1 to 11, a container

therefor, and instructions for the use of the pharmaceutical formulation in the treatment of female scalp hair loss or in hormonal replacement therapy.

5        28. In combination, a pharmaceutical formulation  
as claimed in any one of claims 1 to 11, a topical  
treatment substantially as described in any of the  
Examples relating thereto, a container therefor, and  
instructions for the use of the pharmaceutical  
10 formulation in the treatment of female scalp hair  
loss or in hormonal replacement therapy.

15

20


25

30

35

# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 85/00218

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC <sup>4</sup> : A 61 K 31/57; A 61 K 7/06		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC <sup>4</sup>	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	Unlisted Drugs, volume 23, nr. 2, February 1971, (Chatham, New Jersey, US) see page 27m "Verafem" --	1-28
X	Unlisted Drugs, volume 15, nr. 11, November 1963, (Chatham, New Jersey, US) see page 87h "Nogest" --	1-28
X	Rote Liste, 1969, (Editio Cantor, Aulendorf/Württ. see page 1377 "Weradys" and page 1391 "Zylo-Farlutal" --	1-28
X	EP, A, 0033164 (VON KISTOWSKI, Irmgard) 5 August 1981, see page 5, claims 1-5 --	1-28
A	US, A, 3942641 (EUGENE J. SEGRE) 9 March 1976, see column 9, line 38- column 10, line 38; claims 1-7 --	1-28
A	DE, A, 2757024 (TAMM, Jürgen) 28 June 1979 -----	1-28
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
22nd August 1985	10 SEP. 1985	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 G.L.M. Kruvdenberg	

## ANNEX TO THE INTERNATIONAL SEARCH REPORT

INTERNATIONAL APPLICATION NO.

PCT/GB 85/00218 (SA 9713)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 03/09/85

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0033164	05/08/81	DE-A- 3003036	30/07/81
US-A- 3942641	09/03/76	NL-A- 7305734	26/10/73
		FR-A,B 2182992	14/12/73
		DE-A,B 2319850	08/11/73
		GB-A- 1384214	19/02/75
		AU-A- 5466473	24/10/74
		US-A- 3932635	13/01/76
		CA-A- 1012061	14/06/77
DE-A- 2757024	28/06/79	None	

For more details about this annex :  
see Official Journal of the European Patent Office, No. 12/82

*This Page Blank (usptc*